Alteogen Researches Subcutaneous Cancer Drug Delivery
New methods for delivering antibody-drug conjugates aim to shift cancer therapy from intravenous infusion to home injection.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Would you prefer self-administering medical injections at home over visiting a clinic for intravenous treatment?
Alteogen has presented new research on subcutaneous delivery methods for antibody-drug conjugates at the European Society for Medical Oncology event in Madrid. The development, currently in the research stage, aims to shift administration of these cancer therapies from intravenous infusions to subcutaneous injections.
Why it matters
Transitioning antibody-drug conjugates to subcutaneous administration could significantly increase patient convenience by enabling self-administration. This shift targets the high clinical burden of current intravenous protocols which require professional medical oversight.
The market for antibody-drug conjugates is projected to grow from 12 billion dollars in 2024 to 57 billion dollars by 2032. Alteogen's subcutaneous research is aimed at capturing a portion of this expansion.
The players
Alteogen
A biotechnology firm that develops proprietary delivery platforms and biologic drug formulations.
European Society for Medical Oncology
A leading professional organization for medical oncology that hosts research summits and sets international standards for cancer treatment.
The details
Alteogen utilizes its proprietary ALT-B4 technology to modify antibody-drug conjugates—complex molecules that combine a targeting antibody with a cytotoxic drug—into formulations suitable for subcutaneous injection. Animal experiments conducted to test this delivery method showed that the technology enables uniform drug dispersion while reducing skin damage at the injection site. This mechanism allows the drugs to be administered under the skin, such as in the abdomen or thighs, rather than through systemic venous access.
Timeline
2024: Market size for antibody-drug conjugates was 12 billion dollars.
October 26, 2026: Alteogen presented its research at the European Society for Medical Oncology.
October 27, 2026: The European Society for Medical Oncology event concludes.
2032: Market size is projected to reach 57 billion dollars.
The Tech Race
The transition of biologic therapies to subcutaneous delivery is a major focus for oncological research presented at the European Society for Medical Oncology. This work places Alteogen in direct competition with established intravenous administration standards to improve patient access.
Patients may eventually be able to self-administer these cancer therapies at home, eliminating the need for clinical intravenous infusions. This development remains in the research stage, and clinical timelines for human availability have not been established.
The takeaway
Alteogen is testing a transition to subcutaneous injections for complex antibody-drug conjugates to simplify cancer care. Watch for clinical trial data to confirm if these animal-model successes hold in human patients.
Further reading
Explore the latest developments in drug delivery innovation in our Biotech section.
Source note: This article includes information reported by 조선일보.
Live Poll
Would you prefer self-administering medical injections at home over visiting a clinic for intravenous treatment?
